drugset / Trial / NCT01793610

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610

Phase 2 Completed 29 enrolled Resilient Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this clinical trial is to learn if MDMA in combination with therapy is safe and effective in people with chronic, treatment-resistant PTSD. The main questions it aims to answer are: * Does MDMA-assisted therapy reduce PTSD symptoms? * Is there a difference in PTSD symptoms between the 40 mg, 100 mg, and 125 mg groups? Researchers will compare two active doses (100 mg and 125 mg) of MDMA-assisted therapy versus a comparator dose of 40 mg MDMA-assisted therapy to determine if there is a reduction in PTSD symptoms. Participants will undergo three non-drug preparatory sessions, three MDMA-assisted therapy sessions and three non-drug integrative therapy sessions after each MDMA-assisted therapy session.

Timeline

Start
2013-05-13
Primary completion
2015-12-03
Completion
2017-02-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Midomafetamine Unknown 40 mg Oral
Comparator Midomafetamine Unknown 100 mg Oral
Comparator Midomafetamine Unknown 125 mg Oral